Literature DB >> 21666501

Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth.

Brent A Orr1, Haibo Bai, Yazmin Odia, Deepali Jain, Robert A Anders, Charles G Eberhart.   

Abstract

The hippo pathway and its downstream mediator yes-associated protein 1 (YAP1) regulate mammalian organ size in part through modulating progenitor cell numbers. YAP1 has also been implicated as an oncogene in multiple human cancers. Currently, little is known about the expression of YAP1 either in normal human brain tissue or in central nervous system neoplasms. We used immunohistochemistry to evaluate nuclear YAP1 expression in the fetal and normal adult human brains and in 264 brain tumors. YAP1 was expressed in fetal and adult brain regions known to harbor neural progenitor cells, but there was little YAP1 immunoreactivity in the adult cerebral cortex. YAP1 protein was also readily detected in the nuclei of human brain tumors. In medulloblastoma, the expression varied between histologic subtypes and was most prominent in nodular/desmoplastic tumors. In gliomas, it was frequently expressed in infiltrating astrocytomas and oligodendrogliomas but rarely in pilocytic astrocytomas. Using a loss-of-function approach, we show that YAP1 promoted growth of glioblastoma cell lines in vitro. High levels of YAP1 messenger RNA expression were associated with aggressive molecular subsets of glioblastoma and with a nonsignificant trend toward reduced mean survival in human astrocytoma patients. These findings suggest that YAP1 may play an important role in normal human brain development and that it could represent a new target in human brain tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21666501      PMCID: PMC3130608          DOI: 10.1097/NEN.0b013e31821ff8d8

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  34 in total

1.  Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.

Authors:  Barbara S Paugh; Chunxu Qu; Chris Jones; Zhaoli Liu; Martyna Adamowicz-Brice; Junyuan Zhang; Dorine A Bax; Beth Coyle; Jennifer Barrow; Darren Hargrave; James Lowe; Amar Gajjar; Wei Zhao; Alberto Broniscer; David W Ellison; Richard G Grundy; Suzanne J Baker
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

2.  Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres.

Authors:  Eli E Bar; Alex Lin; Vasiliki Mahairaki; William Matsui; Charles G Eberhart
Journal:  Am J Pathol       Date:  2010-07-29       Impact factor: 4.307

3.  CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma.

Authors:  Yin Xu; Ivan Stamenkovic; Qin Yu
Journal:  Cancer Res       Date:  2010-03-02       Impact factor: 12.701

4.  The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation.

Authors:  Ian Lian; Joungmok Kim; Hideki Okazawa; Jiagang Zhao; Bin Zhao; Jindan Yu; Arul Chinnaiyan; Mason A Israel; Lawrence S B Goldstein; Ramzey Abujarour; Sheng Ding; Kun-Liang Guan
Journal:  Genes Dev       Date:  2010-06-01       Impact factor: 11.361

5.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

6.  Expression of Yes-associated protein in common solid tumors.

Authors:  Angela A Steinhardt; Mariana F Gayyed; Alison P Klein; Jixin Dong; Anirban Maitra; Duojia Pan; Elizabeth A Montgomery; Robert A Anders
Journal:  Hum Pathol       Date:  2008-08-13       Impact factor: 3.466

7.  Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma.

Authors:  Michelle Z Xu; Tzy-Jyun Yao; Nikki P Y Lee; Irene O L Ng; Yuk-Tat Chan; Lars Zender; Scott W Lowe; Ronnie T P Poon; John M Luk
Journal:  Cancer       Date:  2009-10-01       Impact factor: 6.860

Review 8.  The hippo signaling pathway in development and cancer.

Authors:  Duojia Pan
Journal:  Dev Cell       Date:  2010-10-19       Impact factor: 12.270

9.  Influence of fat-hippo and notch signaling on the proliferation and differentiation of Drosophila optic neuroepithelia.

Authors:  B V V G Reddy; Cordelia Rauskolb; Kenneth D Irvine
Journal:  Development       Date:  2010-07       Impact factor: 6.868

10.  The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals.

Authors:  Nailing Zhang; Haibo Bai; Karen K David; Jixin Dong; Yonggang Zheng; Jing Cai; Marco Giovannini; Pentao Liu; Robert A Anders; Duojia Pan
Journal:  Dev Cell       Date:  2010-07-20       Impact factor: 12.270

View more
  61 in total

Review 1.  Recent Advances of the Hippo/YAP Signaling Pathway in Brain Development and Glioma.

Authors:  Taohui Ouyang; Wei Meng; Meihua Li; Tao Hong; Na Zhang
Journal:  Cell Mol Neurobiol       Date:  2019-11-25       Impact factor: 5.046

2.  Yes-associated protein 1 is activated and functions as an oncogene in meningiomas.

Authors:  Gilson S Baia; Otavia L Caballero; Brent A Orr; Anita Lal; Janelle S Y Ho; Cynthia Cowdrey; Tarik Tihan; Christian Mawrin; Gregory J Riggins
Journal:  Mol Cancer Res       Date:  2012-05-22       Impact factor: 5.852

Review 3.  YAP and the Hippo pathway in pediatric cancer.

Authors:  Atif A Ahmed; Abdalla D Mohamed; Melissa Gener; Weijie Li; Eugenio Taboada
Journal:  Mol Cell Oncol       Date:  2017-02-25

4.  c-Yes regulates cell adhesion at the apical ectoplasmic specialization-blood-testis barrier axis via its effects on protein recruitment and distribution.

Authors:  Xiang Xiao; Dolores D Mruk; C Yan Cheng
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-11-20       Impact factor: 4.310

5.  Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness.

Authors:  Nicholas Artinian; Cheri Cloninger; Brent Holmes; Angelica Benavides-Serrato; Tariq Bashir; Joseph Gera
Journal:  J Biol Chem       Date:  2015-05-21       Impact factor: 5.157

Review 6.  Role of Yes-associated protein 1 in gliomas: pathologic and therapeutic aspects.

Authors:  Yong-Chang Liu; Yan-zhou Wang
Journal:  Tumour Biol       Date:  2015-03-07

7.  Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression.

Authors:  Tiffany A Melhuish; Izabela Kowalczyk; Arkadi Manukyan; Ying Zhang; Anant Shah; Roger Abounader; David Wotton
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2018-10-10       Impact factor: 4.490

8.  INSM1 Expression Is Frequent in Primary Central Nervous System Neoplasms but Not in the Adult Brain Parenchyma.

Authors:  Heather M Ames; Lisa M Rooper; John J Laterra; Charles G Eberhart; Fausto J Rodriguez
Journal:  J Neuropathol Exp Neurol       Date:  2018-05-01       Impact factor: 3.685

9.  Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.

Authors:  Weiying Zhang; Nivedita Nandakumar; Yuhao Shi; Mark Manzano; Alias Smith; Garrett Graham; Swati Gupta; Eveline E Vietsch; Sean Z Laughlin; Mandheer Wadhwa; Mahandranauth Chetram; Mrinmayi Joshi; Fen Wang; Bhaskar Kallakury; Jeffrey Toretsky; Anton Wellstein; Chunling Yi
Journal:  Sci Signal       Date:  2014-05-06       Impact factor: 8.192

10.  The Hippo signaling pathway and translational opportunities for brain cancers.

Authors:  Gilson S Baia; Otavia L Caballero; Gregory J Riggins
Journal:  CNS Oncol       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.